Evidence map›Paper›PMID 35314778›Full record

ArticleScientific reports2022

Presence of CrkI-containing microvesicles in squamous cell carcinomas could have ramifications on tumor biology and cancer therapeutics.

Mohamed F Mohamed, Samer Al-Khudari, Puebla Cassini-Vieira, Amani Erra, Reem Bagabas, Thomas Houser, Kerstin Stenson, Mihir Bhayani, Michael J Jelinek, Faraz Bishehsari and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting compensatory proliferation signals in oral cancer.Journal of oral biology and craniofacial research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mohamed F Mohamed *Division of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.
Samer Al-Khudari *Department of Otorhinolaryngology, Rush University Medical Center, Chicago, IL, 60612, USA.
Puebla Cassini-VieiraDivision of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.
Amani ErraDivision of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.
Reem BagabasDivision of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.
Thomas HouserDepartment of Otorhinolaryngology, Rush University Medical Center, Chicago, IL, 60612, USA.
Kerstin StensonDepartment of Otorhinolaryngology, Rush University Medical Center, Chicago, IL, 60612, USA.
Mihir BhayaniDepartment of Otorhinolaryngology, Rush University Medical Center, Chicago, IL, 60612, USA.
Michael J JelinekDivision of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.
Faraz BishehsariDivision of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.
Timothy M KuzelDivision of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA.
Sasha H ShafikhaniDivision of Hematology/Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA. Sasha_Shafikhani@rush.edu.
Rush University Medical Center · US

Funding

Role of immune system in prophylaxis antibiotic's surgical site infection controlR01AI150668 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHAFIKHANI, SASHA H · 2020 to 2024
$2.0M
Molecular dissection of Pseudomonas aeruginosa Exotoxin T virulence functionsR21AI110685 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI SHAFIKHANI, SASHA H · 2015 to 2016
$426k
NIAID NIH HHS R01 AI150668NIAID NIH HHS R21 AI110685
6 · The paper itself

Abstract

Recently, we described a phenomenon whereby apoptotic cells generate and release CrkI-containing microvesicles, which stimulate proliferation in surrounding cells upon contact to compensate for their own demise. We termed these microvesicles "ACPSVs" for Apoptotic Compensatory Proliferation Signaling microvesicles. As immune cells and a majority of current cancer therapeutics destroy tumor cells primarily by apoptosis, we conducted a small pilot study to assess the possibility that ACPSVs may also be generated in squamous cell carcinomas. We first evaluated a primary and a metastatic squamous cell carcinoma cancer cell lines for their ability to produce ACPSVs under normal and apoptotic conditions. We next conducted a pilot study to assess the occurrence of ACPSVs in solid tumors extracted from 20 cancer patients with squamous cell carcinomas. Both cancer cell lines produced copious amounts of ACPSVs under apoptotic conditions. Interestingly, the metastatic squamous cell carcinoma cancer cell line also produced high levels of ACPSVs under healthy condition, suggesting that the ability to generate ACPSVs may be hijacked by these cells. Importantly, ACPSVs were also abundant in the solid tumors of all squamous cell carcinoma cancer patients. Detection of ACPSVs in cancer has potentially important ramifications in tumor biology and cancer therapeutics which warrants further investigation.

Indexed as

Carcinoma, Squamous CellCell-Derived MicroparticlesApoptosisBiologyHumansPilot Projects

Identifiers

PMID35314778
PMCPMC8938485
OpenAlexW4220810987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.